Abstract Treatment of migraine is on the cusp of a new era with the development of drugs
that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its …

Background Migraine is one of the most common neurological disorders that leads to
disabilities. However, the conventional drug therapy for migraine might be unsatisfactory at …

Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the
pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with …

Targeting receptor proteins, such as ligand-gated ion channels and G protein-coupled
receptors, has directly enabled the discovery of most drugs developed to modulate receptor …

Background: The optimal monoclonal antibody against calcitonin gene-related peptide
(CGRP) for adult patients with migraine has yet to be determined. Therefore, we aimed to …

Introduction Since calcitonin gene-related peptide (CGRP) plays an important role in the
pathophysiology of migraine via the activation of the trigeminovascular system, the newest …

Objective The relative effects of monoclonal antibody against calcitonin gene-related
peptide (CGRP) or its receptor for adult migraine patients with prior treatment failure remains …

ABSTRACT Introduction Calcitonin Gene-Related Peptide (CGRP) has gradually emerged
as a suitable therapeutic target to treat migraine. Considering the social and economic …

Migraine is a severe neurovascular disease manifested mainly as unilateral throbbing
headaches. Triptans are agonists for serotonin receptors. Zolmitriptan (ZMP) is a …

Background Patients with high-frequency episodic migraine (HFEM) have a greater disease
burden than those with low-frequency episodic migraine (LFEM). Acute treatment overuse …